Glenmark Pharma discovers new anti-cancer molecule

01 Apr 2011 Evaluate

Glenmark Pharmaceuticals has announced the discovery of a new molecule for oncology treatment and would file an application for phase-I trials in the fourth quarter of FY12. Developed at Glenmark's Switzerland-based research centre, the GBR 401 molecule is an anti-CD19 monoclonal antibody primarily targeted for treating lymphoma and leukemia of B-cell origin. In addition, the molecule also has potential to treat disorders like rheumatoid arthritis. The molecule is in the same segment of anti-cancer biotech product rituximab, which had annual global sales of $6 billion.crackcrack

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×